Andrew is a General Partner at Pangaea Ventures, a world leader in advanced materials venture capital. He has a deep understanding of advanced materials commercialization and has developed deep expertise in helping companies navigate the early growth stage as they work to prove product-market fit, build out high-performance teams, cultivate a culture of excellence, and optimize growth financing. Andrew is also responsible for leading Pangaea's impact strategy and related activities, including the incorporation of impact measurement into due diligence, impact reporting, and portfolio value creation. He currently serves on the Board of a number of Pangaea portfolio companies, including Aspect Biosystems, a bioprinted tissue therapeutics company, and Prime Roots, a meat alternative company. Andrew holds a Bachelor of Applied Science (Mechanical Engineering) from the University of Toronto and an MBA from the Sauder School of Business at the University of British Columbia.

Mr. McDonogh led the spinout of Hinalea from TruTag Technologies, where he has served in lead strategy and business development roles, including as its CEO. Prior to TruTag he served as Vice President, Business Development and Corporate Strategy at Systech International, a serialization, product safety, anti- counterfeiting and brand protection company, where he led the development of Systech's global partnership program to scale its operations internationally. Prior to Systech, he served as the Director of Corporate Development at UDG Healthcare PLC, an international provider of clinical, commercial, communication, and packaging services to the healthcare industry where he drove the commercial development of United Drug subsidiaries in North America. Mr. McDonogh has a BS from University College Dublin and an MBA from University College Dublin's Smurfit Graduate School of Business.

Ms. Deasy has extensive experience in advising high-potential agrifood and life science tech companies, incubators, and VC Funds in Europe. Currently, she sits on the boards of SOLASTA Bio, a precision crop protection company, and Sundew Bio, a biotech venture developing biological solutions for aquatic pests, diseases, and invasive species. Ms. Deasy is also a project lead for the BioInnovation Institute, an incubator that accelerates world-class life science innovation, a financial advisor for VEROVACCiNES, a developer of combi-vaccines for animal health, and serves on the Investment Committee for biotope by VIB, an impact agrifood biotech incubator.

Ms. Deasy is Founder and former Managing Partner at The Yield Lab Europe, one of the largest seed stage agrifood tech impact venture capital funds in Europe, where she headed up the life science and biotech side of the fund’s portfolio. She was also previously Associate Director at KPMG Corporate Finance where she led the Food and Beverage team, and Director of Corporate Finance at Ernst & Young, before establishing Alta Corporate Finance, which specializes in raising seed stage venture capital for life science technology companies, where she was founder and CEO.